

Non-Invasive Prenatal Test - NIPT
 Non-Invasive Prenatal Test - NIPT Microdeletion

(To be filled in by patient)

Vial ID:

Patient	Name	KIRNYA BUI DODUM		Date of Birth	DD/MM/YYYY 13/08/1988	ID/Passport No	940549247071
	Address	TAKIR BUI, LIPU LIKABALI, WEST SIANG, ARUNACHAL PRADESH		Contact number	8132932437		
Weight	58 kg	Blood Type	101 TVE	Inherited Disease	<input checked="" type="checkbox"/> NO <input type="checkbox"/> YES		
Pregnancy	Gestation Period 12 Weeks			Pregnancy type	<input checked="" type="checkbox"/> Singleton <input type="checkbox"/> Multiple		
	Past history of Gestation Abnormality <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes						

(To be filled in by Clinical/Medical Institution)

Pregnancy profile	Doctor	DR. MUKESH FOGLA		Undergoing IVF <input type="checkbox"/> No <input checked="" type="checkbox"/> Yes (Number of embryos: Implantation _____ Blighted ovum _____ Fetal reduction _____)					
	Down Syndrome test	<input type="checkbox"/> none so far <input type="checkbox"/> NT _____		Notes: T21 _____ T18 _____ T13 _____					
Sample info	Medical Institution	ULTRACARE DIAGNOSTICS, DIRUGARH	Contact number	8453036343	Blood taken by	PULAK KALITA		Blood quantity	10 mL
	Blood collection date	05/10/2023	DD/MM/YYYY	Blood pick up date			05/10/2023		
Collection agent			Condition of blood	GOOD		Blood ID	KIRNYA BUI DODUM		

Purpose and method of the test

The FirstVue NIPT (Non Invasive Prenatal Testing) was developed by PathCare Labs. This test is designed to screen for Trisomy 13 (Patau syndrome), Trisomy 18 (Edwards syndrome) and Trisomy 21 (Down syndrome). The test is performed by first collecting a 10 ml blood sample from an expecting mother at least 10 weeks into the pregnancy. Cell-free fetal DNA is then extracted from the blood sample for subsequent DNA sequencing. Through innovative next-generation DNA sequencing technology, and specialized bioinformatics analysis, this test platform has a detection rate of over 99.9% for the above-mentioned genetic anomalies.

Recommended use of this test:

The FirstVue NIPT should be considered after close consultation with your physicians and if possible a genetic counselor.

The test is recommended in cases where:

1. Patients are concerned about the risk of invasive prenatal diagnosis; and/or
2. Patients have unusual ultrasonography findings which suggest chromosome abnormality; and/or
3. Patients are of advanced maternal age and/or have a higher risk of their fetus being diagnosed with Down syndrome.

Test Results:

The test report will indicate a Positive (aneuploidy detected) or Negative (aneuploidy not detected) result for each of the conditions listed above.

In very few cases, the test does not report any results. In these circumstances, PathCare Labs will provide a free re-test. If the re-test...

this NIPT serve as a reference for your physicians to suggest further treatment.

The accuracy and quality of the test may be adversely affected by improper blood sample collection, storage and transportation. Accuracy and quality of the test may also be adversely affected by samples taken from patients that have received medical treatment including allogeneic blood transfusion, transplant operations, and stem cell therapy within 30 days of sample collection.

This test is not suitable for:

- Patients with dizygotic multiple gestation.
- Patients with diagnostic results that have revealed chromosomal aneuploidy.
- Patients who have previously accepted blood transfusions from other than themselves, or have undergone transplantation surgery, stem cell therapy or egg donation.
- Patients at less than 10 weeks gestation.
- Patients who have tested positive for HIV and/or Hepatitis B/C.

Limitations of the test:

Chromosomal abnormalities such as chromosomal rearrangements, duplications, copy number variations, balanced translocations, inversions, imbalanced translocations, uniparental disomy, mosaicism etc., are not within the scope of detection. Therefore, this does not guarantee that a fetus will be free from a genetic disease. NIPT Microdeletion test is a risk assessment test only and does not guarantee that a fetus will be free from genetic microdeletion.

Informed consent:

If the NIPT test result is high risk, PathCare will reimburse the cost of further confirmatory diagnostic tests including amniocentesis and chromosome fluorescence in situ hybridization (FISH).

OBSTETRICAL SONOGRAPHY

Name of Patient : Kirnya Bui

Date : 05.10.2023

A live intrauterine fetus is seen in a gestational sac.

CRL measures : 56.9mm, Corresponding to 12weeks 2days.

Fetal heart rate : 160bpm

Placenta on the posterior wall

Nuchal translucency : 1.2mm

Cervical length : 56.7mm

Both ovaries appears normal



Signature